Stock Ratings / Consumer Staples / GRDN / insiders

CVS (61) YI (37) PETS (19) RDGT (37) ⌘ Pro Terminal →

Guardian Pharmacy Services Inc. (Class A) (GRDN) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$40.69 +0.59% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $40.83

Guardian Pharmacy Services Inc. (Class A) (GRDN) earns a Roarable Rating of B- (Buy) with 71/100 RQD Confidence. High-quality cash engine (20% profit margin, 38% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

📊 Historical Track Record: Scores of 71/100 (B-) historically ranked in the Top 14% of excess returns over the next 90 days (+6.8% avg 90D alpha vs SPY • 68.4% hit rate) →

ROARABLE B- • BUY Cap $2.56B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on GRDN Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is GRDN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Guardian Pharmacy Services Inc. (Class A) (NYSE: GRDN) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 71/100 at a spot price of $40.69 (+0.59% 1D, market cap $2.56B). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 15/20. Across 146 tracked Consumer Staples issuers, GRDN ranks #11 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does GRDN compare to CVS and YI in the Consumer Staples sector?

▼

Within the Consumer Staples sector (Retail-Drug Stores and Proprietary Stores), GRDN carries a Roarable B- (71/100 RQD), trailing P/E of 52.1x, gross margin of 20.2%, and ROIC of 37.7%. By comparison, CVS (CVS Health Corporation) holds a C- grade (61/100 RQD, P/E 65.3x, ROIC 2.6%, cap $115.53B) and YI (111 Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -20.5%, cap $26.2M). Among the 5-stock peer group, GRDN leads on earnings multiple (52.1x) while GRDN leads on capital efficiency (37.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for GRDN?

▼

Per GRDN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001802255), Guardian Pharmacy Services Inc. (Class A) generated $1.45B in revenue (+17.9% YoY), $49.2M in net income, and $100.3M in free cash flow against $412.7M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (20% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Priced at 52x earnings—high expectations leave less room for a lukewarm quarter.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $40.83 (+0.35%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 17/20 (A-) • 6.9% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 71/100 (B-) historically ranked in the Top 14% of excess returns over the next 90 days (+6.8% avg 90D alpha vs SPY • 68.4% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERBUY • B-

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C+ · Rk B

Each axis scored 0–20

12M PRICE TARGET CONE+5.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GRDN)Realized 20D OHLCV Swing Band: ±7.3%

Deterministic 5-Pillar Attribution (71/100 Composite)

🔍 WHY GRDN SCORES 71/100 (B-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (25% of score)

Altman Z-Score 12.39 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+17/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 6.9% FCF Margin ($100.3M FCF) & 20.2% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning9/20 pts (-11 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-11 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C+$40.47-0.8% Next Q

Q2 (-2Q)

Grade B-$40.14-2.4% Next Q

Q3 (-1Q)

Grade B-$39.19+3.8% Next Q

Current

Grade B-$40.69+6.8% Hist 90D α

Trajectory: C+ (63) → B- (71)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the GRDN Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 71/100 (B-) score, GRDN faces multiple-compression risk if 52.1x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Priced at 52x earnings—high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 17.7% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($41.10) or 200D SMA ($38.14) invalidates the momentum regime and cuts Target Base ($43.07) toward Bear Floor ($33.37).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $GRDN• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “GRDN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 71%NO 29%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

GRDN Smart-Money Thermometer: HEAVY INSIDER & 13F ACCUMULATION

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (GRDN)

No recent open-market Form 4 cluster sales or emergency dumps flagged on GRDN. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (GRDN Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

GRDN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +11.05%▲ ASCENDING CHANNEL

2026-11-02O $40.33H $40.69L $40.33C $40.69VOL 208.0K

RES: $49.93SUP: $39.15SMA50: $41.10SMA200: $38.14

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

GRDN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 GRDN Butterfly Map → + Track GRDN →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

37.5%/yr Implied 5Y Growth

vs. +17.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on GRDN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for GRDN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for GRDN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GRDN)

Consumer Staples Rank #11 of 146 ⚔️ CVS vs GRDN Full Matrix →

1. Head-to-Head Consumer Staples Peer Comparison (GRDN vs. CVS, YI, PETS, RDGT)

Industry: Retail-Drug Stores and Proprietary Stores (5 Tracked Issuers)

Across 146 tracked Consumer Staples securities in the Roarable RQD universe, Guardian Pharmacy Services Inc. (Class A) (GRDN) ranks #11 by composite RQD confidence (71/100, grade B-) and #53 by equity capitalization ($2.56B). Within this direct 5-issuer industry benchmark cohort, GRDN leads on earnings valuation at 52.1x trailing P/E, while GRDN leads on capital efficiency and profitability with 37.7% ROIC and 20.2% gross margin. GRDN currently leads its immediate peer cohort in composite quantitative strength at 71/100 (B-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
GRDN ACTIVE Guardian Pharmacy Services Inc. (Class A)	B-	71/100	52.1x	20.2%	37.7%	+0.59%	$2.56B	Benchmark Subject
CVS CVS Health Corporation	C-	61/100	65.3x	45.0%	2.6%	-0.09%	$115.53B	/cvs-vs-grdn →
YI 111 Inc.	D-	37/100	—	5.8%	-20.5%	-4.36%	$26.2M	/yi-vs-grdn →
PETS PetMed Express Inc.	E	19/100	—	28.1%	-35.0%	+0.85%	$25.6M	/pets-vs-grdn →
RDGT Ridgetech Inc.	D-	37/100	—	3.6%	—	-3.32%	$3.0M	/rdgt-vs-grdn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001802255

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Guardian Pharmacy Services Inc. (Class A) (GRDN) reported GAAP revenue of $1.45B (+17.9% vs. FY2024 revenue of $1.23B ) , GAAP net income of $49.2M, operating cash flow of $100.3M, and free cash flow of $100.3M (+73.0% YoY). On the balance sheet, GRDN closed FY2025 with $412.7M in total assets against $0 in total debt (Altman Z-Score: 12.39, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$1.45B	$49.2M	$100.3M	$100.3M	$412.7M	—
FY2024 (FY)	2024-12-31	$1.23B	-$110.0M	$58.0M	$58.0M	$320.8M	—

3. GRDN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is GRDN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does GRDN compare to CVS and YI in the Consumer Staples sector?

What are the biggest fundamental strengths and SEC risk factors for GRDN?

Where is GRDN trading relative to its 50-day, 200-day, and 52-week technical levels?

GRDN last traded at $40.69 (+0.59% on volume of 319,046 shares), positioning the stock -1.00% below its 50-day simple moving average ($41.10) and +6.69% above its 200-day simple moving average ($38.14). Across its 52-week range of $26.34 to $48.33, GRDN sits at the 65.3% percentile with a 14-day RSI of 49.3 (NEUTRAL RANGE) and an implied next-earnings move of ±7.3% ($37.72 to $43.66).

GRDN Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are GRDN insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies GRDN leadership and institutional positioning as: HEAVY INSIDER & 13F ACCUMULATION.

Direct Sub-Reports: GRDN RQD Cockpit GRDN 12M Forecast GRDN Earnings & Move GRDN Dividends & DRIP GRDN Insiders & 13F GRDN Whale Options GRDN Profit Sankey GRDN News & Why

ROARABLE RATING BRIEF • RQD 71/100 (B-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

GRDN — Guardian Pharmacy Services Inc. (Class A): What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:25:27Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, GRDN carries an RQD Score of 71 and a letter grade of B-, labeled "Roarable Buy — Sound Institutional Accumulation." The five pillars are:

Fundamental Cash Engine: 17 / 20. Per the RQD rating, this reflects ROIC of 37.7% and FCF yield of 3.91%. For a prospective investor, the high ROIC against a modest net margin (3.4%) suggests the capital base is used efficiently, but the cash yield is the more conservative reference point for valuation.
Whale 13F Flow: 9 / 20. Per the RQD rating, this pillar captures institutional accumulation and options positioning. The score is the second-lowest of the five; the source data provides no 13F holder detail (see Analyst View section), so the basis for this score cannot be independently verified here.
Insider Conviction: 15 / 20. Per the RQD rating, this reflects SEC Form 4 and Congressional PTR cluster flow. The underlying transaction records are not itemized in the source data.
Macro Regime Fit: 12 / 20. Per the RQD rating, this reflects Beta of 1.0 and sector sensitivity. A beta of 1.0 implies market-level sensitivity to broad moves, not defensive or aggressive positioning.
Forensic Balance Sheet: 18 / 20. Per the RQD rating, this reflects Altman Z of 12.39, Piotroski F of 7/9, and Debt/Equity of 0.5. This is the strongest pillar and supports the view that near-term solvency risk is low per these metrics.

Investor implications. The rating's upside case rests on the cash engine and balance sheet. The valuation tradeoff is significant: per the market data, P/E (TTM) is 52.1 and EV/EBITDA is 34.3, well above typical levels, while FCF yield is 3.91%. The stock has also moved sharply within its 52-week range ($26.34–$48.33), with the current price of $40.45 near the upper portion of that band. The RQD score of 71 is therefore a composite of strong fundamentals and a demanding price, not an endorsement of valuation headroom. The whale-flow and macro pillars score lower, indicating less conviction from institutional and macro inputs.

Snapshot

Price	Market Cap	P/E (TTM)	Forward P/E	EV/EBITDA	EPS (TTM)	Dividend Yield	Beta	52-Wk Range	ROIC %
$40.45	$2.56B	52.1	43.8	34.3	0.78	0%	1.0	$26.34 - $48.33	37.7%

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025 (filed 2025-12-31)	$1448.7M	$72.7M	$49.2M	N/A	$100.3M	$65.6M	N/A
FY 2024 (filed 2024-12-31)	$1228.4M	$-62.9M	$-110.0M	N/A	$58.0M	$4.7M	N/A

Per the SEC financials, revenue rose from $1228.4M in FY 2024 to $1448.7M in FY 2025, and the company moved from an operating loss of $-62.9M and net loss of $-110.0M to operating income of $72.7M and net income of $49.2M. Per the market data, gross margin is 20.2%, operating margin 5%, and net margin 3.4%, with ROIC of 37.7%. Per the RQD rating, the Altman Z-Score is 12.39 and the Piotroski F-Score is 7/9, with Debt/Equity of 0.5. Balance sheet detail (debt and EPS line items) is not itemized in the reported periods.

Recent Catalysts & News Wire Analysis

Price-action and outlook coverage (YELLOW): Multiple news items reference a stock climb of 38% and a "Lifts Full Year Outlook" headline, with commentary on whether the stock is fully priced or may trade at a discount.
Earnings event (YELLOW): A transcript of the Q2 2026 earnings conference call and a notice of Q3 2026 results with a conference call are listed.
Revenue estimate (YELLOW): A TradingView item cites a Q3'26 revenue estimate of 365.76M USD.
Raised guidance (GREEN, CATALYST): The most material item flagged as a catalyst is a Simply Wall St piece on how raised guidance affects investors.

Risk watch items: The valuation commentary ("may trade at a discount," "fully priced") indicates that the market has already priced in part of the upside. Proprietary signals: None are listed in the Butterfly Supply-Chain Graph.

Open Questions

What are GRDN's products, customers, and revenue model, given that the source data contains only sector classification and financial aggregates?
What are the drivers of the FY 2024 to FY 2025 swing from operating and net losses to profits, and are they recurring?
Who are the institutional holders and insiders behind the whale-flow (9/20) and insider-conviction (15/20) pillar scores?
What do the raised full-year outlook and Q3 2026 revenue estimate imply for forward earnings, given forward P/E of 43.8?
What is the basis for the EPS (TTM) of 0.78 relative to the reported net income, and what are the EPS and debt figures for the reported periods?

GRDN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Guardian Pharmacy Services Inc. (Class A) (GRDN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to GRDN Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 6h ago

Guardian Pharmacy Services (GRDN) Stock May Trade At a Discount Following a 38% Climb

Yahoo Finance report covering Guardian Pharmacy Services Inc. (Class A) (GRDN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 9h ago

Guardian Pharmacy Services (GRDN) Lifts Full Year Outlook, Is The Stock Fully Priced?

Simply Wall St report covering Guardian Pharmacy Services Inc. (Class A) (GRDN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 12h ago

Transcript: Guardian Pharmacy Service Q2 2026 Earnings Conference Call

Benzinga report covering Guardian Pharmacy Services Inc. (Class A) (GRDN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 15h ago

Guardian Pharmacy Services, Inc. to Report Third Quarter 2026 Financial Results and Host Conference Call

Yahoo Finance report covering Guardian Pharmacy Services Inc. (Class A) (GRDN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 18h ago

GRDN Q3'26 Earnings: revenue estimate is 365.76M USD

TradingView report covering Guardian Pharmacy Services Inc. (Class A) (GRDN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Simply Wall St • 21h ago

How Raised Guidance Will Impact Guardian Pharmacy Services Stock Investors

Simply Wall St report covering Guardian Pharmacy Services Inc. (Class A) (GRDN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ChartMill • 1d ago

AQST News | AQUESTIVE THERAPEUTICS INC (NASDAQ:AQST)

ChartMill report covering Guardian Pharmacy Services Inc. (Class A) (GRDN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Yahoo Finance • 1d ago

What Dis-Chem Pharmacies Doubters Saw Before The Drop

Yahoo Finance report covering Guardian Pharmacy Services Inc. (Class A) (GRDN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

GRDN Bull vs. Bear Conversation Board — What's Your Call at $40.69?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON GRDN 🐻 33% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐂 BULLISH 🎯 Target: $47.73 (+18.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is GRDN (B- • RQD 71/100) a Buy at $40.45?

Welcome to the GRDN (Guardian Pharmacy Services Inc. (Class A)) Roar Pit. Current RQD Composite is 71/100 (Roarable Buy — Sound Institutional Accumulation) in Retail-Drug Stores and Proprietary Stores. Bulls point to capital efficiency (37.7% ROIC), while bears focus on valuation multiple compression (52.1x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

BE BearTrap_Alert Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $31.15 (-23.0%)

Spot @ $40.45

Pump the brakes on GRDN — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on GRDN, but look at what you are paying: 52.1x trailing P/E with 20.2% gross margins. Unless Guardian Pharmacy Services Inc. (Class A) expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $48.94 (+21.0%)

Spot @ $40.45

GRDN cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on GRDN, the market is fixating on short-term headline noise in Retail-Drug Stores and Proprietary Stores and ignoring the balance sheet and cash flow trajectory. At $40.45 (52-wk range $26.34 - $48.33), any beat on forward guidance forces shorts and underweight funds to chase.